Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7788935 | 0.91 | DRD2 (0.50) | DRD2DRD4DRD3POLBHTR2C | |
| SCHEMBL9367707 | 0.76 | DRD2 (0.51) | DRD2DRD4DRD3KMT2AHTR2C | |
| SCHEMBL7792010 | 0.75 | DRD2 (0.58) | DRD2DRD4DRD3HTR2CHTR2A | |
| SCHEMBL7783722 | 0.75 | DRD2 (0.58) | DRD2DRD4DRD3HTR2CHTR2A | |
| SCHEMBL13648741 | 0.75 | DRD2 (0.60) | DRD2DRD4DRD3POLBHTR2C | |
| SCHEMBL13648727 | 0.75 | DRD2 (0.62) | DRD2DRD4DRD3POLBKCNH2 | |
| SCHEMBL7783724 | 0.75 | DRD2 (0.54) | DRD2DRD4DRD3KMT2AHTR2C | |
| SCHEMBL7812646 | 0.72 | HTR2C (0.60) | DRD2DRD4HTR2CALDH1A1HTR2A | |
| SCHEMBL7792762 | 0.72 | DRD2 (0.56) | DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL9373785 | 0.71 | DRD2 (0.49) | DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0613465-B1 | 1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER LAMBERT CO (US) | 2001-10-04 | — | — | EP | claimed |
| JP-3193718-B2 | — | — | 2001-07-30 | — | — | JP | claimed |
| US-5409931-A | Dopaminergic, antipsychotic and antihypertensive agents | WARNER-LAMBERT COMPANY (US) | 1995-04-25 | — | — | US | claimed |
| EP-0613465-A1 | 1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-09-07 | — | — | EP | claimed |
| EP-0545095-A1 | 1,3-Substituted cycloalkenes and cycloalkanes as central nervous system agents | WARNER-LAMBERT COMPANY (US) | 1993-06-09 | — | — | EP | claimed |
| WO-1993010092-A1 | 1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-05-27 | — | — | WO | claimed |
| EP-0613465-B1 | 1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER LAMBERT CO (US) | 2001-10-04 | — | — | EP | disclosed |
| US-5409931-A | Dopaminergic, antipsychotic and antihypertensive agents | WARNER-LAMBERT COMPANY (US) | 1995-04-25 | — | — | US | disclosed |
| EP-0613465-A1 | 1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-09-07 | — | — | EP | disclosed |
| US-5314896-A | Dopaminergic agents, antipsychotic and hypotensive agents | WARNER-LAMBERT COMPANY (US) | 1994-05-24 | — | — | US | disclosed |
| EP-0545095-A1 | 1,3-Substituted cycloalkenes and cycloalkanes as central nervous system agents | WARNER-LAMBERT COMPANY (US) | 1993-06-09 | — | — | EP | disclosed |
| WO-1993010092-A1 | 1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-05-27 | — | — | WO | disclosed |